Omnicell Inc Q4 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Scott Shaw - KeyBanc Capital Markets - Analyst : Thanks for the. Hi team. So first question, the first quarter guidance, how much of that assumes the remaining, you know XT within that product revenues' growth, maybe just walk through a little bit of what that new guidance growth assumes. And then also, I was wondering as you, you're switching to more expansion throughout the rest of the year after you, fully complete the XT series cycle with expansions and more modular solutions. Shouldn't that help on the gross margin side? Just kind of want to work applications on the gross margin side. Thanks.

Question: Scott Shaw - KeyBanc Capital Markets - Analyst : Great, thanks.

Question: Stan Berenstein - Wells Fargo - Analyst : Hi, thanks for taking my questions. Randy. It was nice to see that you're making progress on the robotic compounding capabilities that you called out in the prepared remarks. I guess what needs to happen for the compounding robot to move beyond the early adopter stage into a more widescale release? And is there a timeline for this happening?

Question: Stan Berenstein - Wells Fargo - Analyst : Helpful. And then your competitor is expecting to release the new dispensary cabinets that, that it has this year. Are you seeing any increase in RFPs for your C cabinets from health systems that perhaps you're not part of your install base?

Question: Stan Berenstein - Wells Fargo - Analyst : Great. And then maybe one quick one from Nchacha. Just any comments on capital deployment priorities over the next 12 months?

Question: Scott Shaw - KeyBanc Capital Markets - Analyst : Great. Thanks so much.